



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/568,409

09/26/2006

Atanas Iliev Lalev

13993-4

7611

1059 7590 02/19/2010
BERESKIN AND PARR LLP/S.E.N.C.R.L., s.r.l.
40 KING STREET WEST
BOX 401
TORONTO, ON M5H 3Y2
CANADA

EXAMINER

LUM, LEON YUN BON

ART UNIT

PAPER NUMBER

1641

MAIL DATE

DELIVERY MODE

02/19/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/568,409	Applicant(s) LALEV ET AL.	
	Examiner Leon Y. Lum	Art Unit 1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 22 October 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-26, 29-32 and 34-52 is/are pending in the application.
- 4a) Of the above claim(s) 29-31, 36, 41-44 and 47-52 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-26, 32, 34-35, 37-40, 45-46 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 14 February 2006 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Specification

The amendment to the specification filed October 22, 2009 has been acknowledged and entered.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was

Art Unit: 1641

not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 32 and 39-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent Publication No. 2004/0142488 to Gierde *et al.* ("Gierde") in view of U.S. Patent No. 7,379,820 to Sukits *et al.* ("Sukits").

i. Independent claim 1 is obvious

Gierde describes a method for performing affinity chromatography, in which an affinity molecule fixed on a column captures a biomolecule. See paragraphs 0083-0092. The biomolecule can be a multi-protein complex. See paragraphs 0195-0201; Table 1. With this description, Gierde teaches steps (a)-(b). Gierde also teaches step (c) by describing a wash step. See paragraph 0137. One or more constituents of the multi-protein complex can be recovered. See paragraph 0200.

Gierde does not, however, teach first and second ligands that associate through electrostatic forces or recovering one of the constituents through decreasing the electrostatic force between it and the rest of the multi-protein complex.

Sukits describes a series of protein pairs – e.g., TRADD and RIP, FAS and FADD, and TNFR-1 and TRADD – that associate together *in vivo* through electrostatic interaction, but can be separated by using NaCl to disrupt the electrostatic interaction. See column 18, lines 30-38.

Art Unit: 1641

With the foregoing description in mind, one of ordinary skill in the art would have found it obvious to modify Gierde's method to investigate protein-protein interactions in a multi-protein complex using the affinity chromatography assay. By combining Gierde and Sukits, Gierde's method would be modified to include a NaCl elution step on an immobilized protein-protein complex. In this manner, the NaCl elution would separate one protein within the complex from other proteins. The skilled artisan would have been motivated to make the modification because Gierde indicates that the nature of multi-protein complexes can be analyzed by eluting individual components, and the skilled artisan would recognize that reducing electrostatic interaction between proteins is one way of recovering protein constituents. Moreover, because Gierde does not limit the elution to any particular method, the skilled artisan would have had a reasonable expectation of success in combining Sukits's technique with the affinity chromatography method of Gierde.

ii. Dependent claims 32 and 39-40 are obvious

Regarding claim 32, Gierde describes the step of repeating the assay with cell lysates. See paragraphs 0138 and 0155.

Regarding claims 39-40, Gierde describes enzyme and polypeptide interactions. See paragraph 0091.

Claim 37 is rejected under 35 U.S.C. 103(a) as being unpatentable over Gierde in view of Sukits as applied to claims 1 and 34 above, and further in view of U.S. Patent Application Pub. 2003/0229212 to Fahrner *et al.* ("Fahrner").

NaCl acts as a competitor for heparin, as evidenced by Gierde and Fahrner. Gierde indicates that in ion-exchange chromatography, an analyte can be eluted by displacement using a salt. See paragraph 022. Fahrner describes an ion-exchange chromatography as a competition between an ion and a substrate for a molecule of interest. See paragraph 0008. Here, NaCl is used as an elution medium against two proteins in a multi-protein complex. See *supra* rejection of claim 1. In light of Gierde and Fahrner, the NaCl competes with the complex to elute a protein in the multi-protein complex, thereby binding to one of the proteins and meeting the claimed limitation.

Claims 1-23, 25-26, 34-35 and 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rigaut *et al.*, Nature Biotechnology (1999) 17:1030-1032 ("Rigaut"), cited in the IDS filed May 30, 2006, in view of Sukits and Gierde.

i. Independent claims 1-4 are obvious

Rigaut describes a tandem affinity purification method comprising the following steps: (1) fusing DNA encoding a TAP tag to DNA encoding a target protein, thereby creating a construct; (2) introducing the construct into a host cell or organism; (3) expressing the TAP-tagged target protein; (4) preparing an extract with the TAP-tagged target protein (corresponding to the claimed "second ligand"); and (5) performing a two-step affinity purification process in which (i) the TAP-tagged target protein is bound to a first affinity column through a first tag, (ii) the target protein is then cleaved from the first tag and bound to a second affinity column through a second tag, and (iii) the target protein is then eluted from the second column; wherein a wash step is performed after

Art Unit: 1641

during each of the separation steps to remove contaminants. See page 1030 (entire page). The target protein prior to the affinity separation steps can be bound to another protein (corresponding to the claimed “first ligand”). *Id.* (Figure 1, depicting the target protein attached to “associated proteins”). The TAP-tagged protein and other protein come into contact *in vivo*, prior to the extraction step. *Id.* (describing the tandem affinity purification method as a useful tool to investigate protein complexes). Accordingly, the TAP-tagged protein “associates *in vivo*” with the other protein as claimed.

With the above description, Rigaut teaches steps (a)-(c) of claim 1, steps (a)-(e) of claim 2 and steps (a)-(h) of claim 3. Moreover, regarding claim 4 and the claimed “fusion protein complex comprising two or more subunits of which are fused to different affinity tags that can selectively bind to different affinity matrixes,” this limitation is interpreted to include multiple proteins since the second ligand is defined in the claims as a protein complex. Rigaut indicates that the two tags can be placed on different proteins in a complex. See page 1031 (right column, second paragraph). Accordingly, Rigaut teaches steps (a)-(h) of claim 4.

Rigaut does not, however, teach first and second ligands that associate through electrostatic forces or a step of separating the first and second ligands by decreasing the electrostatic force between them (i.e., step (d) of claim 1, step (e) of claim 2, step (i) of claim 3 and step (i) of claim 4).

Sukits describes a series of protein pairs – e.g., TRADD and RIP, FAS and FADD, and TNFR-1 and TRADD – that associate together *in vivo* through electrostatic

Art Unit: 1641

interaction, but can be separated by using NaCl to disrupt the electrostatic interaction.

See column 18, lines 30-38.

Gierde describes eluting protein constituents from a multi-protein complex, in order to analyze the nature of the complex. See paragraph 0201. The complex is bound to an affinity column. See paragraph 0196.

With the foregoing description in mind, one of ordinary skill in the art would have found it obvious to modify Rigaut's method to investigate protein-protein interactions in multi-protein complexes using electrostatic elution. By combining Rigaut with Sukits, Rigaut's method would be modified to include a NaCl elution step on a multi-protein complex. In this manner, the NaCl elution would separate at least one protein constituent from other proteins in the complex. The skilled artisan would have been motivated to make the modification because Gierde indicates that the nature of multi-protein complexes can be analyzed by eluting individual components, and the skilled artisan would recognize that reducing electrostatic interaction between proteins is one way of recovering protein constituents. Moreover, because Gierde indicates that different types of elutions can be used in affinity chromatography, the skilled artisan would have had a reasonable expectation of success in combining Sukits and Gierde's technique with the tandem affinity separation method of Rigaut.

ii. Dependent claims 5-23, 25-26, 34-35 and 38 are obvious

With respect to claim 5, Gierde teaches an antibody affinity molecule that binds to a protein antigen within a multi-protein complex. See Table 1.

Art Unit: 1641

With respect to claims 6-7, 14-15 and 20-21, the TAP tag comprises Staphylococcus Protein A that can bind to IgG. See Rigaut, page 1030; Figure 1. Regarding claims 20-21, It would have been obvious to one of ordinary skill in the art to use protein A as either the first or second affinity ligand - i.e., switch positions with calmodulin binding peptide, since the purpose of Rigaut is simply to utilize dual-dimension affinity chromatography. Indeed, the genetic procedure to recombinantly produce the TAP tag could have placed protein A closer to the target protein

With respect to claims 8-9 and 16-19, the TAP tag comprises calmodulin binding peptide, which can be separated from the protein via EGTA. *Id.* Moreover, TEV protease is used to cleave protein A from the calmodulin binding peptide. *Id.* Regarding claims 16-19, It would have been obvious to one of ordinary skill in the art to use the calmodulin binding peptide as either the first or second affinity ligand - i.e., switch positions with protein A, since the purpose of Rigaut is simply to utilize dual-dimension affinity chromatography. Indeed, the genetic procedure to recombinantly produce the TAP tag could have placed calmodulin binding peptide closer to the target protein.

With respect to claims 10-11, TEV protease is used to cleave the TAP-tagged protein from the first affinity separation column. *Id.*

With respect to claim 12, Gierde describes that an extraction step which removes analyte from the affinity column can involve binding of the analyte to a specific cognate molecule. See paragraph 0143. One of ordinary skill would have found it obvious to use the same antibody coated on the affinity column as the specific cognate molecule.

Art Unit: 1641

Indeed, because the coated antibody has known affinity for the analyte, the skilled artisan would have recognized that using the same antibody for the specific cognate molecule would produce the extraction sought.

With respect to claim 13, Gierde describes a method of performing step elutions, in which sequential elutions are performed using different types of gradients. See paragraphs 0181-0187. The gradients can be in any order and not required to be performed in a particular sequence. See paragraph 0185 (describing a first elution by increasing ionic strength and a second elution by affinity binding, but not limited to these specific elution gradients).

With the foregoing description in mind, one of ordinary skill in the art would have found it obvious to modify Rigaut and Sheehan's method by performing sequential elutions using ionic strength and affinity binding in that order. In making the combination, Rigaut and Sheehan's method of sequential Protein A and calmodulin binding peptide would be reversed – i.e., the first affinity separation would utilize calmodulin binding peptide and the second affinity separation would utilize Protein A. Because Rigaut teaches a split TAP tag that places the two tags on different subunits, the skilled artisan would have recognized that Gierde's teaching of sequential elutions can be applied to bind the protein complex using the tags in any order. Accordingly, it would have been obvious to modify Rigaut and Sheehan's method using Gierde in the manner described. The skilled artisan would have made the modification because Rigaut indicates that TAP is an alternatively way of performing tandem affinity separation, *see supra* rejection of claim 4, and Gierde implies that two dimensional

Art Unit: 1641

separations can be performed using a variety of elutions not in any particular order.

Moreover, because all references are directed to affinity column separation, the skilled artisan would have had a reasonable expectation of success in combining the references.

With respect to claims 22 and 23, the NaCl gradient incorporates an increasing ionic strength gradient, especially since the objective is to separate one protein from the other. *See supra* rejection of claim 1.

With respect to claims 25 and 26, because Sukits describes an NaCl elution medium, it would have been obvious to one of ordinary skill in the art to select a change in concentration using the ranges claimed. Indeed, the skilled artisan would have arrived at the claimed ranges based on the doctrine of routine optimization. In a case decided by the precursor to the Federal Circuit, the court stated that a claim is not allowable where the skilled artisan could have arrived at the claim through routine experimentation on the optimum or workable ranges of the claim. *In re Aller*, 220 F.2d 454, 456 (CCPA 1955) (stating "where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.") In *Aller*, the claims were directed to a process taught by the prior art, except for a specific temperature and acid concentration range. *Id.* The court held, however, that the claims were not patentable because the skilled artisan could have arrived at the claimed ranges through routine optimization. Similar to that case, Rigaut, Sukits and Gierde teach all the limitations of claims 25 and 26, except for a concentration range. Lacking evidence to the contrary, it would have been within the

Art Unit: 1641

routine skill of the skilled artisan to optimize the concentration ranges of the NaCl elution compound to arrive at the claimed ranges.

With respect to claim 34, NaCl is capable of separating one protein from the other, thereby having "capability" to separate the "first ligand from the second ligand," as claimed. *Id.*

With respect to claim 35, Sukits describes a mutation. See column 18, lines 43-45. As held by the Supreme Court in *KSR International Co. v. Teleflex Inc.*, 127 S.Ct. 1727, 82 USPQ2d 1385 (U.S. 2007), an obvious to try rationale is proper, given a "finite number of identified, predictable solutions." *KSR* at 1397. Indeed, the Court stated that in such a case, "a person of ordinary skill has good reason to pursue the known options within his or her technical grasp." *Id.* Here, as would have been recognized by one of ordinary skill in the art, it would have been obvious to try a mutated FADD protein in order to analyze the interaction of the protein with FAS.

With respect to claim 38, one of ordinary skill in the art would have found it obvious to include an electrostatic charge identical to a mutation (species (b) in the claim) since the object of the combination of Rigaut, Sukits and Gierde is to separate the protein constituents. Moreover, because Rigaut teaches a gradient, see *supra* rejection of claim 1, the skilled artisan would have found it obvious to include the claimed electrostatic charge in the range of NaCl concentrations.

Claim 24 is rejected under 35 U.S.C. 103(a) as being unpatentable over Rigaut in view of Sukits and Gierde as applied to claims 1 and 22-23 above, and further in view of

Art Unit: 1641

U.S. Patent No. 5,007,934 to Stone and U.S. Patent No. 5,849,885 to Nuyens *et al.* ("Nuyens").

Rigaut, Sukits and Gierde (together "Rigaut") do not teach a KCl chemical agent.

Stone describes using NaCl or KCl as equivalent salts for removing glycoprotein or proteoglycan associated with collagen through electrostatic interaction. See column 7, lines 60-66.

Nuyens describes NaCl or KCl as equivalent salts for reducing electrostatic interactions between lactoferrin and other proteins. See column 4, lines 51-60.

With the foregoing description in mind, one of ordinary skill in the art would have found it obvious to modify Rigaut's method to use KCl as the eluting compound instead of NaCl. The skilled artisan would have performed the modification because it is well known in the art to use KCl as a substitute for NaCl for disrupting electrostatic interactions between proteins, as evidenced by Stone and Nuyens. For the same reason, the skilled artisan would have had a reasonable expectation of success in substituting KCl for NaCl.

Claims 45 and 46 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rigaut in view of Sukits and Gierde as applied to claim 1 above, and further in view of U.S. Patent 6,610,508 to Hentze *et al.* ("Hentze") and evidenced by U.S. Patent No. 5,753,225 to Clary *et al.* ("Clary").

Rigaut, Sukits and Gierde (together "Rigaut") do not teach the step of identifying protein-protein association as a putative cause for Alzheimer's disease.

Art Unit: 1641

Clary describes receptor-ligand complexes as reversible electrostatic attractions.

See column 10, lines 66-67; column 11, lines 1-11.

Hentze describes a step of identifying protein-protein interactions in order to detect disease states, including Alzheimer's disease. See column 1, lines 33-54; column 30, lines 58-62,

With the foregoing description in mind, one of ordinary skill in the art would have found it obvious to modify Rigaut's method to include the step of identifying protein-protein interactions for detecting Alzheimer's disease. The skilled artisan would have made the modification because detecting Alzheimer's disease informs a patient whether the disease state is present. Moreover, the skilled artisan would have had a reasonable expectation of success because protein-protein interaction is a type of ligand-receptor interaction, which is known to be a reversible electrostatic attraction. See Clary, column 11, line 10. Hentze's technique would therefore fit well with Rigaut's method utilizing electrostatic interactions.

Response to Arguments

Applicant's arguments, see pages 11-19 of the Response, filed October 22, 2009, with respect to the rejection of the pending claims under 35 U.S.C. 103(a) have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground of rejection is made in view of Gierde, Sukits and Rigaut. This action is being made non-final.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leon Y. Lum whose telephone number is (571) 272-2872. The examiner can normally be reached on Monday to Friday (8:30 am to 5:00 pm).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark L. Shibuya can be reached on (571) 272-0806. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Leon Y. Lum/
Examiner, Art Unit 1641

Application/Control Number: 10/568,409

Page 15

Art Unit: 1641

/Unsu Jung/

Primary Examiner, Art Unit 1641